European Heart Journal Advance Access published online on February 9, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn023
Usefulness of clinical and NT-proBNP Monitoring for prognostic guidance in destabilized heart failure outpatients
1 Department of Cardiology, University Hospital Virgen de la Arrixaca, Ctra. Madrid-Cartagena s/n, 30120 Murcia, Spain
2 Department of Medicine, Universitat Autonoma de Barcelona, University Hospital Santa Creu i Sant Pau, Barcelona, Spain
3 Department of Bioquimica, University Hospital Virgen de la Arrixaca, Ctra. Madrid-Cartagena s/n, 30120 Murcia, Spain
4 Statistics Department, University Hospital Santa Creu i Sant Pau, Barcelona, Spain
5 Department of Bioquimica, Universidad Autonoma de Barcelona, University Hospital Santa Creu I Sant Pau, Barcelona, Spain
6 Department of Cardiology, Massachusetts General Hospital, Boston, USA
Received 12 July 2007; revised 27 July 2007; accepted 10 January 2008.
* Corresponding author. Tel: +34 968369445, Fax: +34 968369662, Email: dapascual{at}servicam.com
Aims: To study the relative prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) monitoring in addition to clinical disease severity scores (CDSSs) in outpatients with destabilized heart failure (HF).
Methods and results: Seventy-one outpatients with recently destabilized HF were recruited. At baseline, and at all following visits, a CDSS based on Framingham criteria was obtained, and NT-proBNP levels were measured in a blind fashion. CDSS did not correlate with NT-proBNP levels at any time (P > 0.1), although their relative changes correlated during follow-up (P < 0.001). Forty patients (56%) had clinical events (cardiovascular death and/or HF hospitalization) within 1 year of follow-up. Changes in CDSS from baseline were not predictive of subsequent events (P > 0.1 for all visits), whereas changes in NT-proBNP levels were predictive at several time points: week 2 (P = 0.005), week 3 (P = 0.037), week 4 (P = 0.015), and 6 months (P = 0.026). A change in NT-proBNP levels at follow-up week 2 (%) added independent prognostic information (P < 0.001, HR 0.982, 95% CI 0.972–0.992) to baseline CDSS (P = 0.002, HR 2.05, 95% CI 1.290–3.266), age (P = 0.007, HR 1.034, 95% CI 1.009–1.059), and left ventricular ejection fraction (P = 0.013, HR 0.942, 95% CI 0.898–0.987).
Conclusion: Serial monitoring for per cent change in NT-proBNP concentrations offers superior prognostic information to clinical assessment among outpatients with recent destabilized HF.
Key Words: B-type natriuretic peptide • Clinical score • Heart failure • Outpatient • Prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Pascual-Figal, J. Ordonez-Llanos, P. L. Tornel, R. Vazquez, T. Puig, M. Valdes, J. Cinca, A. B. de Luna, A. Bayes-Genis, and on behalf of the MUSIC Investigators Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2174 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Niessner, P. J. Hohensinner, K. Rychli, S. Neuhold, G. Zorn, B. Richter, M. Hulsmann, R. Berger, D. Mortl, K. Huber, et al. Prognostic value of apoptosis markers in advanced heart failure patients Eur. Heart J., April 1, 2009; 30(7): 789 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Squire Assessing prognosis in heart failure: you can see a lot if you look, but more if you look again ... ... ... Eur. Heart J., April 2, 2008; 29(8): 959 - 960. [Full Text] [PDF]
|
|